Three negative breast cancer no standard program

Navigation:Home > Internal Oncology > Mammary Cancer > Three negative breast cancer no standard program

Three negative breast cancer (TNBC) refers to estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor

Content

Three negative breast cancer (TNBC) refers to estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) are negative in patients with breast cancer. A poor prognosis, 5 years survival rate is less than 15%, higher risk organs, brain metastasis, histological grade were grade 3, a higher proportion of cell proliferation, c-kit, p53, EGFR expression is positive, basal cell markers CK5/6 and CK17 are mostly positive. Tumor invasion is strong, and local recurrence and distant metastasis are easy to occur. There are many similarities between breast cancer and BRCA1 mutation associated with basal like breast cancer.

The present study shows that three negative breast cancer "endocrine therapy and trastuzumab targeted therapy, treatment mainly rely on chemotherapy. Compared with other types of breast cancer, three negative breast cancer is more sensitive to chemotherapy and radiotherapy, but the prognosis is still poor. There are no guidelines for the treatment of three negative breast cancer, and the treatment is generally based on poor prognosis.

NBC in neoadjuvant chemotherapy can be obtained from 12% to 48% of the pathological complete response rate (pCR), higher than other types of breast cancer, but its pCR fluctuations in the literature reports. The application of adjuvant chemotherapy in the early stage of TNBC is still controversial, and some scholars advocate the use of non anthracycline chemotherapy. Paclitaxel, anthracyclines and other cytotoxic drugs are still the main drug of TNBC rescue chemotherapy. Clinical trials have shown that the combination of gemcitabine and capecitabine can prolong the survival time of patients. ADP- ribose polymerase (PARP) has become a new target of TNBC targeted therapy, and further studies on its inhibitors such as BSI-201 and Olaparib are expected to provide more effective choices for clinical treatment.

 

www.Cure001.comwww.Cure999.com

Cerebral Vascular Disease,Acne,Heart Disease,Deaf,Headache,Std,Condyloma Acuminatum,Fibroid,Pneumonia,Brain Trauma,。 Rehabilitation Blog 

Rehabilitation Blog @ 2017